Abstract Background and purpose Single Dose Radiation Therapy (SDRT) provides
remarkably high rates of control even for tumors resistant to fractionated radiotherapy. SDRT
tumor control depends on acute acid sphingomyelinase-mediated endothelial cell injury and
monoclonal antibodies targeting Vascular Endothelial Cell Growth Factor (VEGF) signaling
radiosensitized tumor endothelium when delivered immediately prior to irradiation. Here we
evaluate the ability of the oral VEGF receptor inhibitor, axitinib, to sensitize tumor …